Ten trials, from a search ending in May 2022
The authors searched five bibliographic databases for randomized trials, then selected ten trials from 439 records screened. Two researchers independently extracted the data and assessed the risk of bias.
The supplied record is dated November 13, 2026, but the literature search ends in May 2022. This review therefore cannot describe findings from trials published after that search. Only the PubMed abstract was consulted, not the full text.
Perceived relief, not a demonstrated improvement in lung function
Compared with control groups, opioids are associated with reduced breathlessness. The standardized mean difference is −0.4, with a 95% confidence interval ranging from −0.6 to −0.2. According to the authors, this effect exceeds the minimum threshold considered clinically important.
This measure combines results reported on different scales. It represents neither a 40% reduction in breathlessness nor an individual's probability of experiencing relief. The abstract provides no absolute result that would clarify how many patients experience an improvement.
However, the analyses show no statistically significant effect on forced expiratory volume in one second, a measure of lung function, or on exercise capacity. The lack of a significant result does not prove there is no effect at all, but no benefit has been established for these outcomes.
An add-on option, not a first-line treatment
The authors consider opioids only as an add-on treatment for certain patients with advanced COPD and persistent breathlessness despite optimal standard treatment. Their conclusion is not a general recommendation for anyone experiencing breathlessness.
The abstract does not detail adverse effects, interactions, treatment durations or the total number of participants. It therefore does not allow the balance of benefits and risks to be established here, particularly over the long term. Funding and conflicts of interest could not be verified.
Limitations to keep in mind
Ten old, small and clinically heterogeneous trials. The dossier contains only the PubMed abstract, without sufficient details on comparators, durations, safety or funding. The literature search ends in May 2022.
What we can take away
This review suggests a benefit for refractory breathlessness in COPD, with no demonstrated benefit for lung function or exercise capacity. It is not enough to justify routine opioid use.
Sources and provenance
- Efficacy of opioid therapy in the management of chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Source date: 2026-11-13.
Journal Article, Systematic Review, Meta-Analysis · Résumé PubMed uniquement, texte intégral non consulté


